Question-and-Answer Session
Operator
(Operator Instructions) Your first question comes from Ren Benjamin - Rodman & Renshaw.
Ren Benjamin – Rodman & Renshaw
You mentioned, having a plan ready for discussion at the hearing. You mentioned one particular item, the reverse split you try to address and stay on the NASDAQ, can you comment or talk about any other options you may have besides your reverse splits?
Steven King
At the NASDAQ hearing from my understanding they want to understand your clinical programs, your goals, your future milestones that you plan to achieve, which I think we have a very strong position in. In addition they just want to make sure of a stand back position that you do have a reverse stock split in place or available to you, to either a upcoming shareholding meeting or an existing shareholder meeting that you can address the minimum bid deficiency at that point in time when it’s necessary and the reminder of the continued listing requirements, we easily meet or exceed all the other standards from the NASDAQ capital market standpoint.
Ren Benjamin – Rodman & Renshaw
On the clinical side if we are just starting off with Bavi and the oncology program. On the Docetaxel trial can you tell me what short of patients are being treated here? You mentioned advanced breast cancer patients, but are they docetaxel refractory or how should we characterize them?
Steven King
No. Patients in the study have not received prior docetaxel treatment. They are more refractive to agement therapy and this is front line metastatic treatment.
Ren Benjamin – Rodman & Renshaw
Okay, front line metastatic; and so what sort of the response rate would you expect with docetaxel alone?
Steven King
Yes, in the study we based our study on docetaxel had a response rate of about 30% and in that study which was the Avastin study they saw the combination of Avastin plus, docetaxel with about a 50% response rate.
Ren Benjamin – Rodman & Renshaw
That’s overall response rate including FD’s?
Steven King
That is the objective response rate, though the partial responses are complete responses.
Ren Benjamin – Rodman & Renshaw
Regarding the non-small cell lung cancer study, can you talk to us a little bit about when we might see when enrollment might complete and when we might see data and just a little bit of information on the trial design?
Steven King
- To read the full transcript on Seeking Alpha, click here »
